COVID-19 Coagulopathy: Excess Thrombosis and Bleeding?

Rates of bleeding were as high as rates of thromboembolism in a large retrospective study of hospitalized COVID-19 patients.

The coagulopathy associated with COVID-19 has been associated with elevated D-dimer and fibrinogen levels as well as with mild thrombocytopenia and modest, if any, prolongations of prothrombin time (PT) or partial thromboplastin time (PTT). In addition, excess venous thromboembolism (VTE) and arterial thromboembolism (ATE), as well as microvascular thrombosis and clotting of circuits and vascular access, have been well described. In response to the thrombotic burden, some institutions have advised empirical therapeutic- or intermediate-dose anticoagulation, with the understanding that rates of bleeding were perceived to be low in previous retrospective studies.

To further examine rates of both thrombosis and bleeding in this setting, investi…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

COVID-19 Coagulopathy: Excess Thrombosis and Bleeding?

Topics

Reviewing Author